Fulcrum Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 76
- Market Cap
- $552.5M
- Website
- http://www.fulcrumtx.com
Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)
- Conditions
- Facioscapulohumeral Muscular Dystrophy (FSHD)
- Interventions
- Drug: Placebo oral tablet
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Fulcrum Therapeutics
- Target Recruit Count
- 260
- Registration Number
- NCT05397470
- Locations
- 🇺🇸
University of California Irvine, Irvine, California, United States
🇺🇸University of California Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸Kennedy Krieger Institute, Baltimore, Maryland, United States
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir
- Conditions
- Sickle Cell DiseaseSickle Cell Anemia
- Interventions
- Drug: Pociredir oral capsule(s)
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Fulcrum Therapeutics
- Target Recruit Count
- 70
- Registration Number
- NCT05169580
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Foundation for Sickle Cell Disease Research, LLC, Hollywood, Florida, United States
Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets
- Conditions
- Healthy Adult Subjects
- Interventions
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- Fulcrum Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT05002231
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
Safety, Tolerability and Pharmacokinetics of FTX-6058
- Conditions
- Healthy Adult SubjectsSickle Cell Disease
- Interventions
- Drug: FTX-6058/placebo oral capsule(s)Drug: FTX-6058 - Two Dosing Periods
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Fulcrum Therapeutics
- Target Recruit Count
- 109
- Registration Number
- NCT04586985
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc. - Healthy Adults Subjects Only, Overland Park, Kansas, United States
🇺🇸Atlanta Center for Medical Research - Sickle Cell Subjects Only, Atlanta, Georgia, United States
Losmapimod Safety and Efficacy in COVID-19
- Conditions
- COVID-19
- Interventions
- Drug: Placebo oral tablet
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Fulcrum Therapeutics
- Target Recruit Count
- 52
- Registration Number
- NCT04511819
- Locations
- 🇲🇽
Nuevo Hospital Civil de Guadalajara, Guadalajara, JC, Mexico
🇵🇪Hospital Nacional Carlos Alberto Seguín Escobedo - EsSalud Arequipa, Arequipa, AR, Peru
🇺🇸University of Miami, Miami, Florida, United States
Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)
- Conditions
- Facioscapulohumeral Muscular Dystrophy (FSHD)
- Interventions
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Fulcrum Therapeutics
- Target Recruit Count
- 76
- Registration Number
- NCT04264442
- Locations
- 🇪🇸
Hospital UiP La Fe, Valencia, Spain
🇫🇷CHU de NICE- CHU pasteur2, Nice, France
🇪🇸Hospital de la Sta Creu i St Pau, Barcelona, Spain
Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)
- Conditions
- Facioscapulohumeral Muscular Dystrophy (FSHD)
- Interventions
- Drug: Placebo oral tablet
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Fulcrum Therapeutics
- Target Recruit Count
- 80
- Registration Number
- NCT04003974
- Locations
- 🇺🇸
University of California Irvine, Irvine, California, United States
🇺🇸Kennedy Krieger Institute, Baltimore, Maryland, United States
🇺🇸University of Washinton Medical Center, Seattle, Washington, United States
Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Fulcrum Therapeutics
- Target Recruit Count
- 14
- Registration Number
- NCT04004000
- Locations
- 🇳🇱
Radboud University Medical Center, Nijmegen, Netherlands